Clinical trial · Observational
Clinical Application of Serum Anti-Müllerian Hormone (AMH) Measurements
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to assess the association of Anti-Müllerian hormone (AMH) with polycystic ovarian syndrome, premature ovarian insufficiency and fertility. The main objectives include the following: 1. To study the level of serum AMH in women with PCOS and to evaluate the utility of serum AMH in the diagnosis of PCOS. 2. To evaluate the level of serum AMH in women with POI and to evaluate the utility of serum AMH in the management of POI. 3. To evaluate the associations of basal AMH level with FSH level and AFC respectively for women undergoing ART treatment. 4. To determine the optimal regimen of gonadotropin for ovarian stimulation for women undergoing ART treatment. 5. To evaluate the predictive value of serum AMH in reproductive outcomes including oocyte quality, embryo quality, pregnancy loss, clinical pregnancy and live birth rate in women undergoing ART treatment.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anti-Müllerian Hormone | — | UNRESOLVED | — |
| Fertility Issues | — | UNRESOLVED | — |
| Polycystic Ovarian Syndrome | — | UNRESOLVED | — |
| Premature Ovarian Insufficiency | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Serum anti-Müllerian hormone (AMH) (pmol/L)
- timeFrame
- Within 1 to 2 months after the day of recruitment
- description
- To evaluate the serum AMH level of women who undergo investigation for polycystic ovarian syndrome (PCOS), premature ovarian insufficiency (POI) or subfertility
Secondary outcomes (9)
- measure
- Type of gonadotropin used for ovarian stimulation
- timeFrame
- From the first 1 day to last 1 day of ovarian stimulation during ART treatment
- description
- To assess the type of gonadotropin used for ovarian stimulation for women undergoing ART treatment
- measure
- Total gonadotropin dose used for ovarian stimulation
- timeFrame
- On the last 1 day of ovarian stimulation during ART treatment
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 10 Years
- Maximum age
- 44 Years
Show eligibility criteria text
Inclusion Criteria: * Women attending the Paediatric and Adolescent Gynaecological Clinic and Gynaecological Endocrine Clinic of in the Department of Obstetrics and Gynaecology at the Prince of Wales Hospital for the management of PCOS and POI * Women attending the Assisted Reproductive Technology (ART) Unit of The Chinese University of Hong Kong for ART treatment Exclusion Criteria: * Women with age \<10 or ≥45 * Current or past diseases affecting gonadotropin, sex steroid secretion, clearance and excretion
References
Publications (0)
Data not yet available